Electra Therapeutics (ETRA) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 4 analyst targets
6 firms have rated Electra Therapeutics (ETRA) in the last 3 months: 6 buy, 0 hold and 0 sell. Their average 12-month price target is $33.50, 284.6% above a share price of $8.71, ranging from $30 (HC Wainwright & Co.) to $36 (2 firms). No firm has changed its rating in that time.
Recent analyst ratings
Last 3 months| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Initiated Coverage | Buy | $30.00 | Oct 23, 2026 |
| JP Morgan | Initiated Coverage | Overweight | $36.00 | Oct 22, 2026 |
| TD Cowen | Initiated Coverage | Buy | — | Oct 13, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Oct 13, 2026 |
| Evercore ISI Group | Initiated Coverage | Outperform | $36.00 | Oct 13, 2026 |
| Jefferies | Initiated Coverage | Buy | $32.00 | Oct 13, 2026 |
Frequently asked questions
What is the price target for ETRA stock?
The average 12-month analyst price target for Electra Therapeutics (ETRA) is $33.50, with a high estimate of $36.00 and a low of $30.00, across 4 analysts.
Is ETRA a buy, sell, or hold?
Analysts covering Electra Therapeutics currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for ETRA?
The average price target of $33.50 implies 274.72% upside from the last price of $8.94.
Who has the highest and lowest price target for ETRA?
Among the price targets analysts have published for Electra Therapeutics in the last 3 months, the highest is $36.00 from JP Morgan and Evercore ISI Group and the lowest is $30.00 from HC Wainwright & Co..
Has ETRA been upgraded or downgraded recently?
No. Electra Therapeutics has had no analyst upgrades or downgrades in the last 3 months.
What is the latest analyst rating on ETRA?
On Oct 23, 2026, HC Wainwright & Co. initiated coverage of Electra Therapeutics at Buy with a price target of $30.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

